[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601583":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":151,"collaborators":153,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":11,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":11,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dosing Regimen 1","EXPERIMENTAL",null,[13],"Drug: dupilumab",{"label":15,"type":10,"description":11,"interventionNames":16},"Dosing Regimen 2",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","dupilumab","Administered as defined in the protocol",[9,15],[24,25,26],"DUPIXENT®","REGN668","SAR231893",[28],{"name":29,"affiliation":5,"role":30},"Clinical Trial Management","STUDY_DIRECTOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Clinical Trials Administrator","CONTACT","844-734-6643","clinicaltrials@regeneron.com",[38,52,62,72,82,92,101,111,121,131,141],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":11},"Phoenix Childrens Hospital","RECRUITING","Phoenix","Arizona","85016","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-112.07404,33.44838,{"lat":50,"lon":49},{"facility":53,"status":40,"city":54,"state":55,"zip":56,"country":44,"countryCode":45,"cosmosGeoPoint":57,"geoPoint":61,"contacts":11},"University of California San Francisco (UCSF)","San Francisco","California","94143",{"type":47,"coordinates":58},[59,60],-122.41942,37.77493,{"lat":60,"lon":59},{"facility":63,"status":40,"city":64,"state":65,"zip":66,"country":44,"countryCode":45,"cosmosGeoPoint":67,"geoPoint":71,"contacts":11},"Children's Hospital Colorado","Aurora","Colorado","80045",{"type":47,"coordinates":68},[69,70],-104.83192,39.72943,{"lat":70,"lon":69},{"facility":73,"status":40,"city":74,"state":75,"zip":76,"country":44,"countryCode":45,"cosmosGeoPoint":77,"geoPoint":81,"contacts":11},"GI Care for Kids LLC","Atlanta","Georgia","30342",{"type":47,"coordinates":78},[79,80],-84.38798,33.749,{"lat":80,"lon":79},{"facility":83,"status":40,"city":84,"state":85,"zip":86,"country":44,"countryCode":45,"cosmosGeoPoint":87,"geoPoint":91,"contacts":11},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":47,"coordinates":88},[89,90],-71.05977,42.35843,{"lat":90,"lon":89},{"facility":93,"status":40,"city":94,"state":94,"zip":95,"country":44,"countryCode":45,"cosmosGeoPoint":96,"geoPoint":100,"contacts":11},"Weill Cornell Medicine","New York","10065",{"type":47,"coordinates":97},[98,99],-74.00597,40.71427,{"lat":99,"lon":98},{"facility":102,"status":40,"city":103,"state":104,"zip":105,"country":44,"countryCode":45,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"University of North Carolina, Bioinformatics Building","Chapel Hill","North Carolina","27599",{"type":47,"coordinates":107},[108,109],-79.05584,35.9132,{"lat":109,"lon":108},{"facility":112,"status":40,"city":113,"state":114,"zip":115,"country":44,"countryCode":45,"cosmosGeoPoint":116,"geoPoint":120,"contacts":11},"Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":47,"coordinates":117},[118,119],-75.16362,39.95238,{"lat":119,"lon":118},{"facility":122,"status":40,"city":123,"state":124,"zip":125,"country":44,"countryCode":45,"cosmosGeoPoint":126,"geoPoint":130,"contacts":11},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":47,"coordinates":127},[128,129],-79.93275,32.77632,{"lat":129,"lon":128},{"facility":132,"status":40,"city":133,"state":134,"zip":135,"country":44,"countryCode":45,"cosmosGeoPoint":136,"geoPoint":140,"contacts":11},"Cook Children's Medical Center","Fort Worth","Texas","76104",{"type":47,"coordinates":137},[138,139],-97.32085,32.72541,{"lat":139,"lon":138},{"facility":142,"status":40,"city":143,"state":144,"zip":145,"country":44,"countryCode":45,"cosmosGeoPoint":146,"geoPoint":150,"contacts":11},"University of Virginia","Charlottesville","Virginia","22908",{"type":47,"coordinates":147},[148,149],-78.47668,38.02931,{"lat":149,"lon":148},{"type":152,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[154],{"name":155,"class":6},"Sanofi","100601583","phase-3-a-study-of-dupilumab-in-small-children-with-an-allergic-condition-of-the-esophagus-food-pipe-eosinophilic-esophagitis-100601583",false,"NCT07112378","A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis","A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to \u003C15 kg With Active Eosinophilic Esophagitis","Key Inclusion Criteria:\n\n1. Pediatric patients aged ≥6 months and weighing ≥5 kg and \\\u003C15 kg at screening with active EoE\n2. History of symptom(s) determined by the investigator to be the result of EoE in the month prior to screening, as defined in the protocol\n3. Baseline endoscopic biopsies, performed during the screening period, with a demonstration on central reading of intraepithelial eosinophilic infiltration in at least 2 of the 3 biopsied esophageal regions, as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Prior participation in a dupilumab clinical trial or past or current treatment with dupilumab\n2. Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 6 weeks prior to screening. Patients on a food-elimination diet must remain on the same diet throughout the study\n3. Other causes of esophageal eosinophilia or the following conditions: eosinophilic gastroenteritis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)\n4. Active Helicobacter pylori infection\n5. History of Crohn's disease, ulcerative colitis, celiac disease, or prior esophageal surgery\n6. Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening\n7. History of bleeding disorders or esophageal varices that, in the opinion of the investigator, would put the patient at undue risk for significant complications from an endoscopic procedure\n8. Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline standard of care endoscopy\n\nNOTE: Other Protocol-Defined Inclusion\u002FExclusion Criteria Apply","ALL","6 Months","6 Years",{"count":167,"type":168},20,"ESTIMATED","INTERVENTIONAL",[171],"PHASE3","This study is researching an experimental drug called dupilumab (called \"study drug\"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment.\n\nThe aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)",[174],"Eosinophilic Esophagitis (EoE)",[176,177,178],"Type 2 Inflammatory","Allergic\u002Fimmune-mediated","Esophageal dysfunction","2026-06-17",{"date":181,"type":182},"2026-06-18","ACTUAL",{"date":184,"type":182},"2025-11-10",{"date":186,"type":168},"2028-10-09",{"name":5,"class":6},11]